page2011posterabstracts.docVIP

PAGE2011 Poster Abstracts Poster: Absorption and physiology-based PK 13 I-10 Christian Bartels Population PK Model for Pooled Data of Different Oral Diclofenac Formulations 13 I-35 Vicente G. Casabo Bioequivalence trials simulation to select the best analyte for acetylsalicylic acid 14 I-62 Kristin Dickschen Pharmacogenomics of Tamoxifen In Female Patients: A PBPK Model-based Investigation Including The Three Main Metabolites 16 II-20 Ludivine Fronton Monoclonal Antibody Disposition beyond Target Binding: Impact of FcRn on Clearance and Derivation of Mechanistic Compartment Models 18 II-40 Emilie Hénin Meta-analysis of Magnetic Marker Monitoring data to characterize tablet movement through the gastrointestinal tract 20 III-09 Donghwan Lee Development of a population model to describe diurnal and chronokinetic variation in cilostazol pharmacokinetics 22 III-26 Eugeniy Metelkin A Systems Pharmacology Model of Anandamide Dynamics After FAAH Inhibitor Administration 24 III-35 Christoph Niederalt Development of a detailed physiologically based computational kidney model to describe the renal excretion of hydrophilic agents in rats 25 III-40 Kayode Ogungbenro A semi-mechanistic gastric emptying pharmacokinetic model for 13C-octanoic acid: an evaluation using simulation 27 III-54 Anna Pieper Development of a PBPK model of doxorubicin 28 IV-08 Alexander Solms Modelling Inter-Individual Variability in PBPK Models and Deriving Mechanistic Covariate Models for PopPK 30 IV-21 Sonya Tate The Importance of Enterohepatic Recirculation in the Disposition of Pravastatin and Rosuvastatin: A Physiologically-Based Pharmacokinetic Modelling Approach 32 IV-47 Thomas Wendl Development of a physiologically-based pharmacokinetic (PBPK) model for Moxifloxacin and its metabolites in healthy adults 34 IV-65 Kirill Zhudenkov Pharmacokinetics of PEG-IFN Alpha in HCV Infected Patients 36 Poster: Cardiovascular, QT-prolongation 38 III-41 Oliver Ackaert Population modelling of blood pressure: ass